Efficacy

Proven Efficacy Beyond BRCA1

Explore the efficacy ZEJULA can offer patients with ovarian cancer in the following indications1:

 
FDA-approved indications for ZEJULA1

BRCA, breast cancer susceptibility gene; BRCA+, BRCA mutated; BRCA−, not BRCA mutated; HRD, homologous recombination deficiency; HRD+, homologous recombination deficiency positive; HRD−, homologous recombination deficiency negative.

Dosing information

DOSE MODIFICATIONS

See recommendations for dose adjustments

Review Dosing
Safety data

SAFETY DATA

Learn about the safety and tolerability of ZEJULA

See Safety



Reference: 1. ZEJULA (niraparib) [package insert]. Waltham, MA: GSK, Inc; October 2019.